Remimazolam · Byfavo, CNS-7056

What is Remimazolam?

Remimazolam (BYFAVO) is a short-acting benzodiazepine that binds to GABA-A receptors on neuronal membranes. It enhances GABA affinity for the receptor, increasing chloride channel opening and neuronal hyperpolarization to produce sedation.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as

Byfavo, CNS-7056, ONO-2745

Drug type

Small molecule

Targets

GABA-A receptor (GABRA1)

Mechanism

Agonist of GABA-A receptor (GABRA1)

Pathways

GABA signaling, chloride channel opening, neuronal hyperpolarization

Therapy area

Neurology

Developer

Acacia

In trials of

CELZ

FDA status

Approved as Byfavo (July 2, 2020), NDA212295 · FDA label

UNII

7V4A8U16MB

✅ FDA-approved uses

• Induction and maintenance of procedural sedation in adults undergoing procedures lasting 30 minutes or less

From the indications section of the FDA label (version of Feb 20, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Anesthesia, Intravenous

Other drugs acting on GABRA1

Sources

• FDA label (DailyMed)
• FDA label Byfavo (2025-02-20), indications
• NCI Thesaurus
• ClinicalTrials.gov NCT03661489

Updated Oct 3, 2026.